- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04306783
In-Home Sensor Monitoring of Older Adults With Cancer
September 14, 2020 updated by: Washington University School of Medicine
In-Home Sensor Monitoring of Older Adults With Cancer: A Pilot Study
The investigators propose a pilot study of monitoring a sample of 6 older patients receiving active cancer treatment over a period of 6 months with in-home sensor monitors installed and maintained by Foresite Healthcare.
The investigators also propose exploring the beliefs and attitudes of those who are not willing to allow in-home sensor monitoring by asking them to complete a brief survey related to in-home sensor monitoring.
The investigators hypothesize that patients will find the equipment acceptable and unintrusive, that changes in home-monitored patient parameters will precede clinical events and that patient trajectories will be more fully characterized with the in home sensors.
Study Overview
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Arm A:
- Age ≥ 65
- Receiving systemic cancer therapy, including conventional chemotherapy, novel/targeted agents OR will begin systemic therapy within the next 4 weeks.
- Estimated life expectancy >1 year
- Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites
- Willing to have sensors installed in 1-2 primary living areas (e.g. living room and bedroom)
- Continuous home internet connection
- Able to understand and willing to sign an IRB-approved written informed consent document
Arm B:
- Age ≥ 65
- Receiving systemic cancer therapy, including conventional chemotherapy, novel/targeted agents OR will begin systemic therapy within the next 4 weeks.
- Estimated life expectancy >1 year
- Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites
- Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion Criteria:
Arm A:
- Inability to read and understand English
- Only receiving hormonal agents (e.g. anti-estrogen or anti-androgen)
- Lives in institutional setting where instrumental activities of daily living are completed for patient by paid staff
Arm B:
- Inability to read and understand English
- Only receiving hormonal agents (e.g. anti-estrogen or anti-androgen)
- Lives in institutional setting where instrumental activities of daily living are completed for patient by paid staff
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: In-Home Sensor Monitoring
Older adults with cancer undergoing systemic cancer treatment will undergo passive monitoring with motion sensors and bed sensor.
Passive infrared (PIR) motion sensors will be installed in their homes to detect presence in a particular room (e.g., bathroom or kitchen) as well as for specific activities.
There will also be a bed sensor, which is a pneumatic strip installed under the bed linens, which measures displacement of the resident's upper torso as he or she lies on the bed.
Participants will complete a baseline primarily self-administered survey, an abbreviated assessment with each follow up clinic visit (at least once per month) for 6 months of follow up and a final end of study assessment.
|
-Installed and maintained by Foresite Healthcare
|
No Intervention: Arm B: Survey Only
Patients that choose to not proceed with in-home sensor monitoring will be asked to complete a brief survey that explores attitudes regarding in-home sensor monitoring
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of in-home sensor monitoring as measured by a modified version of the Intelligent Systems for Assessment of Aging Technology Survey (Arm A only)
Time Frame: 6 months
|
|
6 months
|
Heart rate (Arm A only)
Time Frame: 6 months
|
-A meaningful change is heart rate outside the normal range of 60-100
|
6 months
|
Changes in gait speed of .1m/s or more (Arm A only)
Time Frame: 6 months
|
6 months
|
|
Stride length (Arm A only)
Time Frame: 6 months
|
6 months
|
|
Number of Falls (Arm A only)
Time Frame: 6 months
|
6 months
|
|
Number of Hospitalizations (Arm A only)
Time Frame: 6 months
|
6 months
|
|
Number of Emergency room visits (Arm A only)
Time Frame: 6 months
|
6 months
|
|
Number of Infections requiring medical intervention (e.g. oral antibiotics) (Arm A only)
Time Frame: 6 months
|
6 months
|
|
Number of grade ≥3 adverse events measured by CTCAE (Arm A only)
Time Frame: 6 months
|
6 months
|
|
Patient reported outcomes of 10 common symptoms (Arm A)
Time Frame: 6 months
|
|
6 months
|
Reason for not choosing in-home monitoring as measured by a modified version of the Intelligent Systems for Assessment of Aging Changes Technology Survey (Arm B only)
Time Frame: At the time of invitation to participate in the study (Day 1)
|
|
At the time of invitation to participate in the study (Day 1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Tanya M Wildes, M.D., MSCI, Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 31, 2020
Primary Completion (Anticipated)
April 30, 2022
Study Completion (Anticipated)
April 30, 2022
Study Registration Dates
First Submitted
November 5, 2019
First Submitted That Met QC Criteria
March 9, 2020
First Posted (Actual)
March 13, 2020
Study Record Updates
Last Update Posted (Actual)
September 16, 2020
Last Update Submitted That Met QC Criteria
September 14, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- 202001189
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on In-home sensor monitoring
-
Federico II UniversityCompleted
-
University of ArizonaQatar National Research Foundation, QatarUnknown
-
US Department of Veterans AffairsCompleted
-
Biotronik Japan, Inc.Completed
-
Biotronik, Inc.CompletedPatient Indicated for an ICDUnited States, Canada
-
Silesian Centre for Heart DiseasesNational Center for Research and Development, PolandCompleted
-
Deutsches Herzzentrum MuenchenCompletedImprovement of Treatment SatisfactionGermany
-
Vanderbilt UniversityCompletedBrain Surgery Requiring Significant Retraction of the BrainUnited States
-
Biotronik SE & Co. KGTerminatedHeart Block | Bradycardia | Sick Sinus SyndromeUnited Kingdom
-
Pennington Biomedical Research CenterLouisiana State University Health Care Services DivisionCompletedHypertension | Obesity | Diabetes | OverweightUnited States